Entropy Technologies’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$893K Sell
18,625
-70,027
-79% -$3.07M 0.04% 440
2025
Q4
$3.43M Buy
88,652
+55,994
+171% +$2.14M 0.19% 154
2025
Q3
$1.15M Sell
32,658
-22,679
-41% -$821K 0.09% 306
2025
Q2
$1.99M Buy
+55,337
New +$1.83M 0.16% 184

Other funds holding RPRX

Entropy Technologies's RPRX Position: Q1 2026 in Review

Entropy Technologies reduced its Royalty Pharma (RPRX) stake by 79% in Q1 2026, selling an estimated $3.07M and leaving 18,625 shares worth $893K. The position accounts for 0.04% of the portfolio, ranked #440.

Entropy Technologies first reported a position in RPRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.43M in Q4 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Entropy Technologies held 18,625 shares of Royalty Pharma worth $893K as of Q1 2026.
  • Entropy Technologies sold 70,027 Royalty Pharma shares in Q1 2026, an estimated $3.07M.
  • Royalty Pharma made up 0.04% of Entropy Technologies's portfolio in Q1 2026, its #440 holding.
  • Entropy Technologies first reported a position in Royalty Pharma in Q2 2025 and has held it in 4 quarters since.
  • Entropy Technologies's Royalty Pharma position peaked at $3.43M in Q4 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.